References
- Bogdanovich T, Esel D, Kelly LM, et al. Antistaphylococcal activity of DX-619, a new Des-F(6)-quinolone, compared to those of other agents. Antimicrob Agents Chemother 2005; 49 (8): 3325–3333.
- Fujikawa K, Chiba M, Tanaka M, et al. In vitro antibac-terial activity of DX-619, a novel Des-Fluoro(6) quinolone. Antimicrob Agents Chemother 2005; 49 (7): 3040–3045.
- Inagaki H, Miyauchi RN, Itoh M, et al. DX-619, a novel des-F(6)-quinolone: synthesis and in vitro antibacterial activity against multi-drug resistant gram-positive bacteria. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract F-1054, p.239. American Society for Microbiology, Washington, DC, USA.
- Watanabe S, Ito T, Hiramatsu K. In vitro activity of novel des-F (6)-quinolone DX-619 against healthcare-associat-ed and community-acquired methicillin-resistant Staphylococci with and without reduced susceptibility to glycopeptide antibi-otics. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract F-1055, p.239. American Society for Microbiology, Washington, DC, USA.
- Hoellman DB, Kelly LM, Smith KA, et al. Antistaphylococcal activity of DX-619 (including against a VRSA strain) compared to eleven other agents. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract F-1056, p.239. American Society for Microbiology, Washington, DC, USA.
- Black JA, Hossain A, Olson LB, et al. Activity of DX-619 against United States clinical isolates of aerobically grow-ing Gram-positive cocci. In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Whashington DC, 2004. Abstract F-1937, p.233. American Society for Microbiology, Washington, DC, USA.
- National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Sixth Edition: Approved Standard M 7-A6. NCCLS, Villanova, PA, USA, 2003.
- Credito KL, Lin G, Bozdogan B, et al. Time-kill study of the antistaphylococcal activity of DX-619 (including a VRSA strain) compared to 8 other agents. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract F-1058, p.240. American Society for Microbiology, Washington, DC, USA.
- Bozdogam B, Appelbaum PC. Activity of DX-619, a new quinolone, against vancomycin non-suseptible Staphylococci. In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 2004. Abstract F-1940, p.234.
- Weller TMA, Andrews JM, Jevons J, et al. The in vitro activity of BMS-284756, a new defluorinated quinolone. J Antimicrob Chemother 2002, 49: 177–184.
- Noviello S, Ianniello F, Leone S, et al. Comparative activity of garenoxacin and other agents by susceptibility and time—kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens. J Antimicrob Chemother 2003; 52: 869–872.
- Wickman PA, Moland ES, Black J, et al. In vitro activi-ty of DX-619, a novel des-fluoro(6) quinolone, against a panel of Streptococcus pneumoniae mutants with characterized resistance mechanisms. Antimicrob Agents Chemother 2006; 50 (2): 796–798.